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Summary
Objective: To assess the measurement properties of the Lequesne index of severity for osteoarthritis of the hip (LISOH) together with its
overall usefulness with reference to the original stated aims.
Method : Postal questionnaire was sent to a random sample of 5500 Oxfordshire residents, aged 65 and above. Respondents with hip
symptoms at baseline (but without veriﬁcation of a diagnosis) were sent an identical follow-up questionnaire 12 months later. The
questionnaire included a general health section, including the Short Form-36 survey, and a hip section which began with a screening question
about hip pain. Respondents who reported having a prolonged episode of hip pain were asked to complete the LISOH.
Results: At baseline, response rate of 66.3% (3341/5039) was obtained from eligible participants; 19.2% (610/3175) of respondents reported
having hip pain. Internal reliability (Cronbach’s alpha) was 0.84 (95% CI: 0.81e0.86) for all 11 items of the LISOH; however, factor analysis
identiﬁed two factors (sub-scales): ‘function and mobility’ and ‘pain and discomfort’. Rasch analysis revealed that the two factors were only
unidimensional when applied to sub-groups of respondents. Convergent validity of the LISOH was questionable, as the ‘function and mobility’
factor was more highly correlated with SF-36 bodily pain score than was the ‘pain and discomfort’ factor. The assessment of sensitivity over
time was problematic due to changing patterns of symptomatic weight-bearing joints over time.
Conclusions: The current study identiﬁes major limitations with the LISOH e particularly if used as a single composite measure.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
The ability to accurately assess severity and change in
peoples’ symptoms, in a standard, reliable and valid way, is
essential to the evaluation of the need for, and response to,
health care interventions. Recognition of this fact, together
with increasing societal demands for evidence of the
beneﬁts (or otherwise) of health care interventions, has
led to an enormous demand for standard, validated health
status measures1.
In order that they might be particularly responsive to
changes in a person’s clinical status, standard assessments
*Address correspondence and reprint requests to: Dr Jill Dawson,
Reader in Health Services Research, School of Health and Social
Care, Oxford Brookes University, Marston Road Campus, Jack
Straws Lane, Oxford OX3 0FL, UK. Tel: 44-1865-227136; Fax: 44-
1865-485297; E-mail: jdawson@brookes.ac.uk
Received 15 March 2005; revision accepted 29 May 2005.85of severity have increasingly been devised that focus on
speciﬁc diseases, conditions, or interventions (e.g., myas-
thenia gravis2, arthritis3, hip replacement4), and the effects
that these have on peoples’ everyday functioning. Such
speciﬁc methods of assessment include standard clinical
assessments e devised and conducted by clinicians, and
patient-based questionnaires, which, in their purest form, are
generated from interviews with patients. Each of these
methods tends to reﬂect different perspectives, to a greater
or lesser extent, as patients and clinicians may differ in terms
of their priorities5.
In order for questionnaires to be considered suitable for
evaluating health care interventions it is now generally
agreed that they should be demonstrated to be reliable,
valid, sensitive to clinical change, and to attract a high rate
of completion6. In addition, if an instrument is to perform
satisfactorily as a single composite scale, ideally, such
a scale should be demonstrably unidimensional i.e., tap4
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of distinct sub-scales7.
This paper evaluates a particular instrument in order to
assess its suitability according to above criteria, as well as
in relation to its original stated aims.
Devised by rheumatologists during the 1980s, the
Lequesne index of severity for osteoarthritis of the hip
(LISOH) is an 11-item questionnaire designed to obtain
information of a subjective nature, from patients, about their
diseased hip. Patients’ responses are then used to
generate a single composite scale8e10. Since its develop-
ment, the LISOH has been widely used. Most often it has
been used as part of an interview/assessment by clinicians.
However, versions to facilitate self-completion have also
been employed (and assessed) in a number of studies11,12.
At the time of its development, the measurement properties
of the LISOH received only very limited attention, although
more recently, some additional evaluations have been
conducted within small scale studies12,13.
The LISOH has three stated purposes10: (1) to facilitate
comparisons based on levels of severity of patients’ hip
symptoms in the trials of new drugs, (2) to evaluate long-
term treatment effects (particularly for hip osteoarthritis
(OA)), and (3) to standardise decision-making regarding the
need for hip replacement.
This paper presents results from an analysis of data
obtained from a large scale population study of hip
symptoms in elderly people14. The analysis assesses the
LISOH questionnaire’s item response and scale properties,
that is: factor structure, dimensionality, internal reliability
and convergent validity. The overall usefulness of the
LISOH is then considered with reference to its stated aims.
Methods
Local research ethics committee approval was obtained
for the study (Applied and Qualitative Research Ethics
Committee (AQREC) reference A01.060).
STUDY POPULATION
A random sample of 5500 Oxfordshire residents, aged 65
and above, was obtained from the Oxfordshire Health
Authority register representing January 2002. A postal
questionnaire and covering letter was sent out to everyone
within a 2-week period in April 2002 and followed up with
two postal reminders (including a second copy of the
questionnaire). Respondents who reported hip symptoms at
baseline were sent an identical follow-up questionnaire 12
months later.
QUESTIONNAIRE
The questionnaire contained a general section which
consisted of a small number of demographic items and the
Anglicised version of the Short Form-36 general health
questionnaire15,16. The SF-36 contains 36 items and is
widely used as a generic health status instrument. It
provides scores on eight dimensions: physical functioning,
role limitations due to physical problems, bodily pain, social
functioning, general mental health, role limitations due to
emotional problems, energy/vitality and general health
perceptions representing the last 4 weeks. Scores for each
dimension range from 0 (poor health) to 100 (good health).
We selected the SF-36 as a measure of general healthstatus because it has been extensively validated, including
in relation to postal administration to elderly populations17,18.
The questionnaire also included a hip section which
began with a screening question that has been used by
others19: ‘‘During the past 12 months, have you had pain in
or around either of your hips on most days for one month or
longer?’’ A separate knee section began with an identically
worded question except that the word ‘knee’ replaced ‘hip’.
Respondents who reported having hip symptoms were
asked to complete the LISOH which had been formatted to
aid self-completion.
The LISOH is a composite measurement score ranging
from 1 to 24 points based on summed responses to 11
items. The score is intended to be calculated separately for
each hip. The ﬁrst ﬁve items are concerned with the
presence of pain and discomfort when remaining in certain
positions or performing particular movements. These in-
clude: pain in bed at night, morning stiffness, walking,
standing for 30 min and sitting for 2 h. Each of these items
offers a maximum of three response categories and relate
to individual joints. As is customary, we therefore included
separate response boxes for the right and left leg. The
remaining six items relate to functional status and include
maximum walking distance and use of a walking aid. These
offer three response categories each, apart from ‘maximum
walking distance’, which offers ﬁve.
In addition to the LISOH, a separate item was added,
which asked patients to rate the pain severity in their
symptomatic hip(s), during the last 4 weeks, on a scale of
1e6 ranging from ‘none’ to ‘very severe’.a The 12-month
follow-up questionnaire was identical to the baseline
questionnaire.
STATISTICAL ANALYSIS
All analyses involving the LISOH have been based on
people who reported having unilateral hip pain (nZ 471),
since we were unable to obtain a single, overall LISOH
score for people with more than one symptomatic hip. The
completion rates of the LISOH and the SF-36 were
calculated to examine the proportion of respondents for
whom a total score could not be calculated due to a missing
response to one or more items within the scale.
Internal reliability of the LISOH was assessed using
Cronbach’s alpha coefﬁcient22 and 95% conﬁdence inter-
vals were calculated using the bootstrap method with
Normal approximation23. This coefﬁcient measures the
extent to which items in a scale correlate with each other
and hence their degree of consistency in measuring the
same underlying construct.
To examine the underlying dimensions of severity
measured by the items of the LISOH, an exploratory factor
analysis (principal components method) was performed,
followed by an oblique (promax) rotation of retained
factors24. Examination of the dimensionality of the LISOH,
and the functioning and ﬁt of individual items, was
undertaken by ﬁtting a Rasch unidimensional measurement
model in RUMM201025. The Rasch model assesses the
unidimensionality of items in a scale based upon the
assumption that, as a person’s disability or symptoms
aA precise rating of pain severity per se is not included within the
LISOH, and Lequesne et al. employed a separate measure in the
form of a visual analogue scale (VAS). We used a rating scale
instead because there is some evidence to suggest that many
elderly people experience difﬁculties with conceptualising and
providing responses using the VAS format 20,21.
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increases26,27.
Convergent validity was assessed by calculating Spear-
man’s rank correlation coefﬁcient for LISOH with the eight
dimensions of the SF-36 and the self-rated pain severity
item. This was repeated using the component factors of the
LISOH from the factor analysis. We hypothesized a strong
correlation of the LISOH with the physical components of
the SF-36 and the self-rated pain severity item, and
a weaker correlation with the mental components of the
SF-36. All analyses were conducted using Stata 8.0 unless
otherwise stated. The signiﬁcance level throughout was set
at two-sided P! 0.05.
Results
STUDY POPULATION
From the original random sample of 5500 people, 3341
completed and returned a questionnaire, giving a response
rate of 66.3% (3341/5039) of those eligible for study
participation. At baseline, 19.2% (610/3175) respondents
reported having hip pain on most days for 1 month or longer
during the last year. The overall response rate obtained for
symptomatic individuals followed up at 1 year was 81.6%
(498/610). Further details of the study design, procedures
and sample have been provided elsewhere28.
For the purposes of this analysis, we were unable to
calculate the LISOH for 21.8% (133/610) of people who
reported hip pain at baseline since they had more than one
symptomatic hip.b We, therefore, excluded from the
analysis people who had bilateral hip pain and calculated
the LISOH for the 471 (77.2%) who had reported only
unilateral hip pain (six people did not provide details on the
number of hips affected and were excluded from the
analysis). This comprised 262 (56%) people who had
reported having a symptomatic knee as well as a symptom-
atic hip and 209 (44%) who only had the single symptomatic
hip (without any knee symptoms). The median (IQR) age of
the unilateral hip cases (nZ 471) was 73 (68e79) years
and 60.5% were females.
COMPLETION AND ITEM RESPONSE RATES
The completion rates for the LISOH and the SF-36 scales
for the 471 cases are presented in Table I. The overall
completion rate for the SF-36 was lower (57.5% SF-36 vs
71.1% LISOH, P! 0.001) due to the larger number of items
(36 vs 11) that had to be completed to permit a total score to
be calculated. However, the completion rates varied across
the different SF-36 sub-scales, all of which obtained better
response rates than the 11-item LISOH.
SCALE PROPERTIES
The Cronbach’s alpha for all 11 items of the LISOH was
0.84 (95% CI: 0.81e0.86). The reliability for the 11 test
scales, each of which representing the overall alpha
excluding each item in turn, is reported in Table II and
show that the removal of any one item did not improve the
overall alpha to any important extent.
The 11 items were entered into an exploratory factor
analysis with principal components extraction and oblique
bThere are no instructions on how to derive an overall index for
each person based on these separate scores.(promax) rotation. Two factors with an eigenvalue greater
than or equal to 1.0 were extracted and the results of this
analysis are shown in Table III.
Most of the six items (items 6e11) relating to the ﬁrst
‘function and mobility’ factor had high loadings (O0.6) while
the ﬁve items (items 1e5) concerned with the second ‘pain
and discomfort’ factor had at least moderately high loadings
(O0.5).
RASCH ANALYSIS
The Rasch analysis was run on three patient groups: (a)
all 471 people reporting a unilateral symptomatic hip with or
without a symptomatic knee, (b) 209 people with a unilateral
hip problem only, and (c) 262 people with a unilateral hip and
a symptomatic knee joint. Initially, a unidimensional Rasch
model was ﬁtted to all 11 items of the LISOH (see Table IV).
In all three groups of patients, the full 11-item Lequesne
questionnaire appeared not to be unidimensional, showing
a highly statistically signiﬁcant deviation from a unidimen-
sional model in each case (P! 0.0001). The Rasch model
Table I
Response rates for the Lequesne hip index compared to the SF-36
dimensions amongst people with one symptomatic hip (nZ 471)
Completion rate* (%)
Number
of items
Unilateral hip cases
Lequesne hip index 11 71.1
SF-36 dimensions
Physical function 10 76.0
Role limitation (physical) 4 87.1
Pain 2 96.2
Energy/vitality 4 86.0
Social function 2 94.3
Role limitation (emotional) 3 88.1
Mental health 5 86.8
General health perception 5 86.2
Total SF-36 scale 36 57.5
*The Lequesne index and separate dimensions of the SF-36
were only computed where people provided responses to every
constituent item.
Table II
Item-total correlation and summary Cronbach’s alpha coefficient (a)
for items of the LISOH amongst people with one symptomatic hip
(nZ 471)
Item Description of item n Item-total
correlation
1 Pain or discomfort in bed at night 390 0.84
2 Morning stiffness or pain 387 0.83
3 Pain when walking 386 0.83
4 Increase in pain when remain standing 382 0.83
5 Pain or discomfort when sitting 388 0.83
6 Maximum walking distance 355 0.82
7 Use of a walking aid 385 0.83
8 Can put on socks 386 0.82
9 Can pick up object from ﬂoor 387 0.81
10 Can go up and down stairs 388 0.81
11 Can get into and out of car 390 0.81
Overall a 0.84
95% Conﬁdence interval* (0.81e0.86)
*Bootrap method with Normal approximation (1000 reps).
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Principal factor loadings for items of the LISOH amongst people
with one symptomatic hip (nZ 471)
Item Description of item Factor loading
1 2
1 Pain or discomfort in bed at night 0.07 0.51
2 Morning stiffness
or pain
0.09 0.52
3 Pain when walking 0.09 0.60
4 Increase in pain
when remain standing
0.03 0.56
5 Pain or discomfort
when sitting
0.07 0.55
6 Maximum walking distance 0.68 0.04
7 Use of a walking aid 0.71 0.10
8 Can put on socks 0.68 0.02
9 Can pick
up object from ﬂoor
0.81 0.03
10 Can go up and down stairs 0.72 0.09
11 Can get into
and out of car
0.59 0.18was next applied to each of the two factors separately. In
the total sample (NZ 471), there was signiﬁcant deviation
from unidimensionality within both the Factor 1 ‘function and
mobility’ (PZ 0.033) and Factor 2 ‘pain and discomfort’
(PZ 0.004) items, suggesting that the items were not
‘tapping’ the same underlying construct. Within Factor 1, the
thresholds of item 6 (maximum walking distance) were not
ordered, suggesting that the responses to this item were not
related to the underlying severity of the condition. In both of
the subsamples, item 6 again showed disordered thresh-
olds. However, there was no signiﬁcant deviation from
unidimensionality in either factor in either subsample.
CONVERGENT VALIDITY
Table V shows the Spearman rank correlation coefﬁ-
cients related to the overall LISOH (11-item) scale and each
of the two sub-scales (factors) with each dimension of the
SF-36 and the separate self-rated pain severity item. All
correlation coefﬁcients shown in Table V were signiﬁcantly
different from zero (P! 0.05). The correlation betweenTable IV
Rasch analysis of LISOH amongst (a) people with one symptomatic hip with or without a symptomatic knee (nZ 471), (b) people with one
symptomatic hip and no symptomatic knee (nZ 209) and (c) people with one symptomatic hip and a symptomatic knee (nZ 262)
All 11 items overall ﬁt to
unidimensional model
Factor 1 (items 6e11) Factor 2 (items 1e5)
(a) NZ 471 (hipG knee) c2Z 188.95, dfZ 77,
P! 0.000001
c2Z 60.44, dfZ 42,
PZ 0.0325
c2Z 48.10, dfZ 25,
PZ 0.0036
Items not properly ordered Item 6 (0.076, 0.235,
0.204, 0.439, 0.485)
Item 6 (0.704, 0.068,
0.149, 0.217, 1.002)
None
Item misﬁt Item 1 c2Z 48.2, P! 0.000001 Item 8 c2Z 13.69, PZ 0.057 Item 1 c2Z 15.4, PZ 0.009
Item 3 c2Z 18.3, PZ 0.0108 Item 4 c2Z 11.7, PZ 0.039
Item 9 c2Z 22.1, PZ 0.0025 Item 5 c2Z 9.83, PZ 0.080
Item 10 c2Z 28.8, PZ 0.0002
Item 11 c2Z 48.2, PZ 0.0011
ResidualO j2j Item 1 residualZ 5.454 None None
Item 2 residualZ 4.046
Item 9 residualZ3.558
Item 10 residualZ3.979
Item 11 residualZ2.530
(b) NZ 209 (hip only) c2Z 104.33, dfZ 22,
P! 0.000001
c2Z 18.79, dfZ 12,
PZ 0.094
c2Z 10.85, dfZ 10,
PZ 0.370
Items not properly ordered Item 6 (0.116, 0.403,
0.377, 0.780, 0.638)
Item 6 (0.537, 0.032,
0.361, 0.330, 1.259)
None
Item misﬁt Item 1 c2Z 18.7, PZ 0.00009 Item 6 c2Z 4.92, PZ 0.085 None
Item 2 c2Z 11.0, PZ 0.0041
Item 3 c2Z 6.09, PZ 0.0477
Item 9 c2Z 10.2, PZ 0.0061
Item 10 c2Z 27.9, PZ 0.000001
Item 11 c2Z 21.1, PZ 0.000028
ResidualO j2j Item 1 residualZ 3.454 None None
Item 2 residualZ 2.232
Item 9 residualZ2.464
Item 10 residualZ3.469
Item 11 residualZ2.854
(c) NZ 262 (hip & knee) c2Z 72.66, dfZ 33,
PZ 0.000083
c2Z 21.85, dfZ 18,
PZ 0.239
c2Z 16.01, dfZ 15,
PZ 0.381
Items not properly ordered Item 6 (0.243, 0.125, 0.103,
0.229, 0.449)
Item 6 (0.836, 0.123,
0.031, 0.153, 0.898)
None
Item misﬁt Item 1 c2Z 17.7, PZ 0.0005 Item 9 c2Z 7.51, PZ 0.057 None
Item 7 c2Z 6.76, PZ 0.0799
Item 8 c2Z 13.6, PZ 0.0035
ResidualO j2j Item 1 residualZ 4.058 None None
Item 2 residualZ 3.593
Item 9 residualZ2.395
Item 10 residualZ2.094
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indicating that the higher (more severe) the respondents’
LISOH, the higher they tended to rate their pain severity.
Correlations with the SF-36 dimensions were all negative,
implying that the higher (more severe) the LISOH, the
worse the respondent’s general health status. The stron-
gest negative correlations were obtained with the physical
function score (0.78) and the SF-36 bodily pain score
(0.65). The weakest negative correlations were with the
mental health score (0.28) and the emotional role
limitation score (0.36).
The ‘function and mobility’ factor (Factor 1) was more
highly correlated with the SF-36 physical function and
physical role limitation scores as compared with the ‘pain
and discomfort’ factor (Factor 2), as might be expected.
Factor 2 was more highly correlated with self-rated pain
severity but, surprisingly, showed less correlation with the
SF-36 bodily pain score compared to Factor 1.
SENSITIVITY OVER TIME
Outcome data for the unilateral cases at 1-year follow-up
are presented in Table VI.
Table VI
Outcome of people with one symptomatic hip (nZ 471) at 1-year
follow-up
Outcome at 1-year follow-up Baseline unilateral
hip cases (nZ 471)
n (%)
Did not complete follow-up
questionnaire or missing data
86 (18.3)
Bilateral hip joint pain 26 (5.5)
No pain in the same unilateral joint 174 (36.9)
Joint pain in same unilateral joint 185 (39.3)
Table V
Correlation of the LISOH with pain severity (self-rated) and the
SF-36 amongst people with one symptomatic hip (nZ 471)
Spearman’s rho correlation coefﬁcient
Lequesne
index
(all 11 items)
Factor 1:
Function
& mobility
(items 6e11)
Factor 2:
Pain &
discomfort
Pain severity (self-rated)* 0.57 0.45 0.59
SF-36 scoresy
Physical functioning 0.78 0.83 0.43
Role limitation
(physical)
0.47 0.50 0.27
Pain score 0.65 0.61 0.48
Energy/vitality 0.49 0.46 0.36
Social functioning 0.61 0.61 0.38
Role limitation
(emotional)
0.36 0.37 0.21
Mental health 0.28 0.29 0.17
General health
perception
0.39 0.43 0.20
*High positive correlation implies agreement as, in both scales,
higher scores denote greater severity.
yHigh negative correlation implies agreement, as higher
Lequesne scores denote greater severity while lower SF-36 scores
denote greater severity.We were unable to examine the sensitivity of the LISOH
to change over time because we could only compare the
baseline and follow-up scores in respondents who had
a one-to-one mapping of scores on the same joint; in other
words, there was an insufﬁcient number of unilateral cases
who reported joint pain in the same unilateral joint 1 year
later, and who also provided complete data for the LISOH
on both occasions. Thus, of the unilateral hip cases, at
baseline, only 185 (39.3%) had joint pain in the same hip 1
year later and just over half of these 106 (57.3%) had
a complete set of item responses for the LISOH.
Discussion
The LISOH was originally designed to be both a site- and
a condition-speciﬁc measure. One stated aim of the LISOH
was that it should be used as an outcome measure in
clinical trials of new drugs to treat OA hip. Indeed, it has
been recommended by Outcome Measures in Rheumatol-
ogy international network for this purpose29. In order for
a questionnaire to be considered suitable for such a purpose
it should be demonstrated to have particular measurement
properties. We undertook an analysis of the LISOH to
assess these properties.
The LISOH is scored to produce a single composite scalee
per hip e although around half of the questions are quite
generic in their focus. In the current study, problems
immediately arose in applying the LISOH in any analysis,
because no instructions are given regarding methods to
combine the scores obtained for both hips that might take
account of the increased impact on health status that arises
where two hips are symptomatic (compared with just one)14.
Studies that have previously used the LISOH have not raised
this issue. A less site-speciﬁc instrument e such as the
Arthritis Impact Measurement scales3 or the Western Ontario
and McMaster Universities (WOMAC)30, would likely be less
problematic if used for evaluating systemic forms of treatment
for OA of weight-bearing joints.
For the particular purposes of this paper, in order to side-
step the practical difﬁculties of applying the LISOH in an
analysis, we used LISOH responses received only from
those people who reported having one symptomatic hip.
Within this subgroup, the overall completion rate for the
LISOH was fairly good (71%), given the elderly status of our
study population. It was, however, somewhat lower than for
each domain of the SF-36. One item, concerned with
maximum walking distance, was clearly particularly prob-
lematic with 25% of respondents leaving this item blank.
Assessed on all people with one symptomatic hip only,
while the internal consistency of the 11-item LISOH was
found to be satisfactory (Cronbach’s a 0.84) for making
group comparisons e where levels of reliability above 0.70
are required, it was not adequate to justify the use of the
LISOH for individual patient assessment e where levels of
reliability above 0.90 have been recommended31e33. This
clearly has implications for another of the stated aims of the
LISOH: to standardise decision-making regarding the need
for hip replacement e in individuals. In fact other instru-
ments e in particular, the New Zealand standard criteria34 e
have been developed speciﬁcally with this purpose in mind
and, while problems remain in using standard question-
naires for this purpose, the New Zealand criteria have been
reported as being helpful in assigning priority for hip
replacement35.
Regarding other measurement properties of the LISOH,
Rasch analysis demonstrated that the index, comprising all
859Osteoarthritis and Cartilage Vol. 13, No. 1011 items, was not unidimensional and exploratory factor
analysis revealed the presence of two sub-scales. How-
ever, when the Rasch model was applied to each of these
sub-scales in turn, there still remained a signiﬁcant de-
viation from unidimensionality within both of the factors
suggesting that the items were not ‘tapping’ the same
underlying construct. Further exploration of sub-groups,
using the Rasch model, did not confer any useful
clariﬁcation of this ﬁnding.
Assessment of the validity of the LISOH in relation to the
SF-36 dimensions revealed one anomalous ﬁnding that
appeared to undermine the validity of the LISOH.
We were unfortunately unable to examine the sensitivity/
responsiveness of the LISOH because there was an
insufﬁcient number of unilateral cases who reported joint
pain in the same unilateral joint 1 year later, and who also
provided complete data for the LISOH on both occasions.
Nevertheless, a previous study has demonstrated the
WOMAC30, to be more responsive than the LISOH12,36.
Our study has a number of limitations14. However, the
main limitation in relation to this paper concerns our case
deﬁnition, as we could not verify that reported hip symptoms
were due to OA. So that, for instance, some peoples’
symptoms, while experienced as coming from the hip, could
have emanated from elsewhere in the body (e.g., the
spine). Nevertheless, our screening question will have at
least identiﬁed cases with symptoms that were not trivial
and the presence of such persistent hip pain in this age-
group, more often than not, represents OA37. Instruments
need to be validated in relation to the type(s) of population
to which they will be applied, and it may be the case that the
Lequesne is only truly suitable for application in a secondary
care specialist setting, where an unequivocal diagnosis of
OA hip can be conﬁrmed. Nevertheless, if this were the
case, it would represent a serious limitation by comparison
with other more versatile instruments (e.g., WOMAC OA
index).
Overall, the LISOH was found to be inadequate in relation
to its measurement properties and this severely limits its
ability to perform in line with the originators’ main aims,
which were probably over ambitious and may even
compete. For instance, it is difﬁcult for a measure to be
both site-speciﬁc (hip) and condition-speciﬁc (OA) as site-
speciﬁc instruments aim to minimise the effects of ‘noise’
(symptoms from other joints, in this instance), while
condition-speciﬁc instruments aim to measure some ‘noise’
directly38. In addition, while the LISOH was designed to
capture the patient’s perspective regarding their hip prob-
lem(s), arguably, questions that are designed to do this are
best generated with patients (by interview), rather than on
behalf of patients (by clinicians)39.
The conclusion of this paper is that investigators need to
choose the most appropriate outcome measures for their
particular purpose. The current study identiﬁes major
limitations with the LISOH e particularly if used as
a composite measure. Investigators wishing to use this
instrument should give serious prior consideration to how
they intend to apply it and to whether it is the most
appropriate measure likely to meet with the speciﬁc aims of
their work.
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